9447例炎症性肠病患者COVID-19疫苗接种的有效性与持久性:系统评价与Meta分析
该系统评价与Meta分析纳入46项研究,评估炎症性肠病患者完整接种COVID-19疫苗后的血清转化率、中和率及突破感染率。完整接种的合并血清转化率为0.96(95%CI 0.94-0.97;I²=90%),合并中和阳性率为0.80(95%CI 0.70-0.87;I²=82%)。大多数研究提示接种4周后抗体滴度下降,且抗肿瘤坏死因子单药或联合免疫调节剂者下降更明显;多数无应答者追加一剂后产生血清学应答。
要点
- 完整接种COVID-19疫苗在多数炎症性肠病患者中可诱导血清转化,合并率为0.96。
- 合并中和试验阳性率为0.80,突破感染相对风险与接种对照组相似。
- 大多数研究提示接种4周后抗体滴度下降,抗肿瘤坏死因子治疗者下降更明显。
核心结论
- 完整COVID-19疫苗接种与多数炎症性肠病患者的血清转化相关。
- 抗体滴度随时间下降,需要考虑追加剂量。
研究设计与样本
- 系统评价与Meta分析,检索电子数据库纳入报告炎症性肠病患者对COVID-19疫苗应答的研究。
- 共纳入46项研究,完整接种血清转化率分析纳入31项研究、9447例患者。
主要发现
- 完整接种的合并血清转化率为0.96(95%CI 0.94-0.97;I²=90%)。
- 与健康对照相比,合并血清转化相对风险较低(0.98;95%CI 0.98-0.99;I²=39%)。
- 不同药物类别间的合并血清转化率在统计学上相似。
- 中和试验合并阳性率(8项研究、771例受试者)为0.80(95%CI 0.70-0.87;I²=82%)。
- 接种的炎症性肠病患者突破感染合并相对风险与接种对照相似(0.60;95%CI 0.25-1.42;I²=79%)。
关键数值与推荐
- 大多数研究提示COVID-19疫苗接种4周后抗体滴度下降,抗肿瘤坏死因子单药或联合免疫调节剂者下降更高。
- 追加一剂COVID-19疫苗可在多数对完整接种无应答者中引发血清学应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 血清转化率合并分析的异质性I²=90%。
- 中和试验合并分析的异质性I²=82%。
- 突破感染相对风险合并分析的异质性I²=79%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The serological responses after severe acute respiratory syndrome coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study aimed to systematically evaluate the seroconversion rates after complete vaccination for coronavirus disease 2019 (COVID-19) in patients with inflammatory bowel disease (IBD). METHODS: Electronic databases were searched to identify studies reporting response to COVID-19 vaccination in IBD. Pooled seroconversion rates after complete vaccination were calculated. Subgroup analysis for vaccine types was also performed. Pooled seroconversion rates for various drugs or classes were also estimated. The pooled rates of breakthrough infections in vaccinated IBD patients were estimated. The pooled neutralization rates after complete vaccination were also estimated. The studies reporting durability of titers were systematically assessed. RESULTS: A total of 46 studies were included. The pooled seroconversion rate for complete vaccination (31 studies, 9447 patients) was 0.96 (95% confidence interval [CI], 0.94-0.97; I2 = 90%). When compared with healthy control subjects, the pooled relative risk of seroconversion was lower (0.98; 95% CI, 0.98-0.99; I2 = 39%). The pooled seroconversion rates were statistically similar among various drug classes. The pooled positivity of neutralization assays (8 studies, 771 participants) was 0.80 (95% CI, 0.70-0.87; I2 = 82%). The pooled relative risk of breakthrough infections in vaccinated IBD patients was similar to vaccinated control subjects (0.60; 95% CI, 0.25-1.42; I2 = 79%). Most studies suggested that titers fall after 4 weeks of COVID-19 vaccination, and the decay was higher in patients on anti-tumor necrosis factor alone or combination with immunomodulators. An additional dose of COVID-19 vaccine elicited serological response in most nonresponders to complete vaccination. CONCLUSIONS: Complete COVID-19 vaccination is associated with seroconversion in most patients with IBD. The decay in titers over time necessitates consideration of additional doses in these patients.
引用
- Jena A, James D, Singh AK, et al. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35189387. doi:10.1016/j.cgh.2022.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。